Welcome to our dedicated page for SHUTTLE PHARMACTCLS HLDGS news (Ticker: SHPH), a resource for investors and traders seeking the latest updates and insights on SHUTTLE PHARMACTCLS HLDGS stock.
Shuttle Pharmaceuticals Holdings Inc (SHPH) is a clinical-stage biopharmaceutical company pioneering radiation-enhancing therapies for cancer treatment. This page provides investors and researchers with timely updates on clinical trials, regulatory milestones, and scientific advancements related to their novel radiation sensitizers and HDAC inhibitors.
Access verified press releases and news about SHPH's pipeline developments, including Ropidoxuridine for glioblastoma and SP-1-303 research. Our curated collection helps stakeholders track progress of therapies designed to improve radiation effectiveness while protecting healthy tissues.
Discover updates on Phase 2 trials, partnership announcements, and peer-reviewed research findings. Content is rigorously verified to ensure accuracy across all stages of drug development – from preclinical studies to regulatory submissions.
Bookmark this page for streamlined access to SHPH's latest innovations in oncology treatment. Check regularly for new developments in their mission to enhance radiation therapy outcomes through targeted pharmaceutical solutions.
Shuttle Pharmaceuticals has appointed Timothy Lorber as the new Chief Financial Officer (CFO), replacing Michael Vander Hoek, who will focus on his role as Vice President, Regulatory. Lorber, a CPA with over 40 years of experience, including significant roles at Legg Mason and Freddie Mac, brings expertise in valuations, M&A transactions, and SEC reporting. He will start as a part-time CFO and transition to full-time by September 10, 2024. Vander Hoek, who has been handling dual roles for four years, will now concentrate on regulatory matters, especially with the upcoming Phase 2 clinical trial.
Shuttle Pharmaceuticals (Nasdaq: SHPH) will participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024. CEO Dr. Anatoly Dritschilo will present updates on the Phase 2 clinical trial of Ropidoxuridine for glioblastoma and the development of predictive biomarkers for prostate cancer by Shuttle Diagnostics, Inc. The webcast presentation will be at 11:00 am ET, with virtual one-on-one meetings available throughout the event. The webcast can be accessed via the conference homepage or directly. Shuttle Pharmaceuticals focuses on enhancing radiation therapy outcomes for cancer patients.
Shuttle Pharmaceuticals Holdings (Nasdaq: SHPH) provided a corporate update for Q1 2024. Highlights include FDA and IRB approvals for a Phase 2 clinical trial of Ropidoxuridine for glioblastoma. The company is finalizing site enrollments with 'first patient, first dose' expected in Q2 2024. Shuttle Pharma also created Shuttle Diagnostics to develop diagnostic tests for prostate cancer, and entered exclusive licensing agreements with Georgetown University for predictive biomarkers. The cash balance as of March 31, 2024, was $4.2 million. Recent presentations were made at the Planet MicroCap Showcase and other investor conferences.
FAQ
What is the current stock price of SHUTTLE PHARMACTCLS HLDGS (SHPH)?
What is the market cap of SHUTTLE PHARMACTCLS HLDGS (SHPH)?
